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Atypical or silent celiac disease may go undiagnosed for many years and can frequently lead to loss of bone mineral density, with
evolution to osteopenia or osteoporosis. The prevalence of the latter conditions, in case of new diagnosis of celiac disease, has been
evaluated inmany studies but, due to the variability of epidemiologic data and patient features, the results are contradictory.The aim
of this study was to evaluate bone mineral density by dual-energy X-ray absorptiometry in 175 consecutive celiac patients at time of
diagnosis (169 per-protocol, 23 males, 146 females; average age 38.9 years). Dual-energy X-ray absorptiometry was repeated after
1 year of gluten-free diet in those with T-score value <–1 at diagnosis. Stratification of patients according to sex and age showed a
higher prevalence of low bonemineral density inmen older than 30 years and in women of all ages. A 1-year gluten-free diet led to a
significant improvement in lumbar spine and femoral neckmeanT-score value.We propose that dual-energy X-ray absorptiometry
should be performed at diagnosis of celiac disease in all women and in male aged >30 years, taking into account each risk factor in
single patients.
1. Introduction
Celiac disease (CD) is a chronic immune-mediated disor-
der, characterized by villus atrophy of the proximal small
intestinal mucosa and malabsorption of nutrients after the
ingestion of wheat gluten or related proteinsin genetically
susceptible individuals expressing the HLA class II molecules
DQ2 or DQ8. Prompt clinical and histologic improvement
is observed following strict adherence to a gluten-free diet
(GFD) [1]. Several extraintestinal manifestations, including
anemia, osteopenia, neurologic symptoms, menstrual abnor-
malities, infertility, recurrent spontaneous abortions, growth
retardation, dermatitis herpetiformis, aphthous stomatitis,
and dental defects, have been associated to CD [2].
In the last decades, screening studies have shown a higher
prevalence of CD than previously thought; up to 1% of the
European and US population are affected at any age and in
a wide variety of clinical circumstances [3, 4]. In the past,
CD was almost always recognized because of its classical
presentation, seen mainly in children, characterized by a
predominance of digestive symptoms like diarrhea, weight
loss, and growth retardation. Today, the presentation of CD
is more frequently atypical, with confusing symptoms or
without symptoms at all. These latter forms may remain
undiagnosed for many years and can lead, among various
consequences, to loss of bone mineral density (BMD) [5].
Since gastrointestinal symptoms, associated disorders, and
complications can be prevented by adherence to dietary
therapy, early recognition of CD is crucial.
Osteoporosis is characterized by severe BMD loss leading
to enhanced bone fragility, and, consequently, atraumatic
fractures. Although this disease can involve any bone, the
hip, spine, and wrist are most likely to be affected with
a remarkable burden for the Public Health System [6].
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Malabsorption syndromes, calcium deficiency, and corticos-
teroids administration are well-known causes of secondary
osteoporosis [7]. Dual-energy X-ray absorptiometry (DXA)
at the femoral neck and lumbar spine is considered the
gold standard to confirm the diagnosis of osteoporosis [8].
Moreover, DXA is one of parameters of FRAX, a diagnostic
tool used to evaluate the 10-year probability of bone fracture
risk [9].
BMD in celiac patients has been evaluated in many
studies but, due to their design, there are several discrepancies
regarding the prevalence of osteoporosis/osteopenia at CD
diagnosis [10, 11]. Since the use of DXA is not justified
in all CD patients, it is crucial to select the population
appropriate for this test [12]. The aim of this study has
been to evaluate the prevalence of abnormalities at DXA
(osteopenia/osteoporosis) in patients with new diagnosis of
CD and to assess the impact of GFD on BMD 1 year after the
diagnosis.
2. Materials and Methods
2.1. Patients. We conducted a prospective study, consisting of
evaluation of BMDusingDXAon 175 consecutive outpatients
with new diagnosis of CD and after 1 year of GFD. Renal
function was normal and none of these patients were on
treatment with calcium or vitamin D.
CD diagnosis was defined using the following cri-
teria indicated by International guidelines: (a) positive
immunoglobulin (IgA) anti-tissue transglutaminase anti-
body (tTG) titers or anti-endomysial antibodies (EmA) [13];
in case of IgA deficiency, IgG anti-tTG titer was deter-
mined; (c) six biopsy specimens were taken from second
part of duodenum during the endoscopic examination; the
degree of mucosal damage was scored according to the
Marsh-Oberhuber classification [14]; for the purpose of the
study, only patients who had classical duodenal mucosal
villus atrophy and crypt hyperplasia (Marsh grade III) were
considered. To guarantee a greater uniformity, the same
expert pathologist analyzed all the samples. Exclusion criteria
included patients with previous diagnosis of CD, use of
immunosuppressive medication (steroids, tacrolimus), hep-
arin, antidepressive agents, surgical menopause, hormonal
and metabolic disorders known as cause of low BMD, and
patients with thyreopathy, liver, or kidney diseases (Figure 1).
No patient had history ofmalabsorption due to inflammatory
bowel disease (IBD) or previous intestinal resections.
Before beginning GFD, the BMD of the lumbar spine
and femoral neck was measured by DXA scanning (Hologic;
Bedford-MA) at Molinette Hospital, Turin, Italy. According
toWHO criteria, aT-score of≥ −1 denotes normal bone, aT-
score between −1 and −2.5 denotes osteopenia, and a T-score
of ≤ −2.5 denotes osteoporosis (Z-score alone is not used to
diagnose osteoporosis in premenopausal women) [15].
After 1 year of GFD (12 ± 1 month) only patients that
showed a T-score value <–1 at diagnosis repeated DXA.
Patients who refused to repeat DXA were excluded from
the final analysis. During this year, neither calcium nor
vitamin D was given to patients. Patients with nonresponsive
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Figure 1: Patients included in the study.
celiac disease (NRCD) (positive IgA anti-tTG or anti-EmA,
in case of IgA deficiency IgG anti-tTG) after 1 year of
GFD were excluded from the final analysis (only in these
patients, excluded from the final analysis, upper endoscopy
with intestinal biopsies was repeated, according to current
guidelines [13]).
2.2. Statistical Methods. Statistical analyses were conducted
using Med Calc version 9.2.1.0 software. The signed rank
sum test (Mann-Whitney test) (independent samples) has
been used to compare different patient groups because size
of groups is different and paired samples 𝑡-test was used to
compare the same group of patients at different times. All
analyses were two tailed and 𝑃 value < 0.05 was considered
significant.
The study was conducted in accordance with ICH-Good
Clinical Practice guidelines, the Declaration of Helsinki, and
local laws and regulations. The protocol was approved by
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Table 1: Baseline characteristics of study population.
Celiac disease (𝑁) 169
Female (𝑁, %) 146, 86.4%
Male (𝑁, %) 23, 13.6%
F/M ratio 6.3 : 1
Average age (years, SD) 38.9 ± 12.6
Premenopausal female (𝑁, %) 104, 61.5%
Postmenopausal female (𝑁, %) 42, 24.9%
𝑁; number.
the appropriate independent ethics committees, and patients
gave written informed consent.
3. Results and Discussion
A total of 169 (23 males, 146 females) outpatients were
considered. The average age was 38.9 years (range 17–75)
(Table 1).
According to WHO criteria, at the time of diagnosis, a
normal DXA at lumbar spine was observed in 71 patients
(42%; T-score mean value −0.1 ± 0.7), whilst 62 were
osteopenic (37%; T-score mean value −1.7 ± 0.4) and 36
osteoporotic (21%; T-score mean value −3.1 ± 0.4) with a
total population mean T-score value of −1.3 ± 1.3. A normal
DXA at femoral neck was observed in 72 patients (43%;mean
value−0.3± 0.6), whilst 75 were osteopenic (44%;mean value
−1.7 ± 0.4) and 22 osteoporotic (13%; mean value −3.1 ± 0.4)
with a total populationmeanT-score value of−1.3± 1.1.There
was no statistically significant difference in mean T-score
values, neither at lumbar spine (𝑃 = 0.43) nor at femoral neck
(𝑃 = 0.48), between females and males, but it is worth noting
that there was a difference of 0.2/0.3 standard deviation (s.d.)
among these groups.
The subdivision of the study population by age and sex
groups (Table 2) showed a higher prevalence of low BMD at
lumbar spine in men older than 30 years and women of all
ages.
There was no statistically significant difference (𝑃 > 0.05)
between the different age groups of males. Contrariwise, in
females there was a significant difference (𝑃 < 0.0001)
between lumbarT-score between over 50 years group and less
than 30 years group (the same for femoral T-scores).
No statistically significant difference was found between
Marsh IIIA e Marsh IIIC (𝑃 = 0.27) in lumbar spine T-
score values as between Marsh IIIA (partial villus atrophy)
and Marsh IIIC (total villus atrophy) (𝑃 = 0.089) in femoral
neck T-score values.
3.1. Patients after 1-YearGluten-FreeDiet. A 1-yearGFD led to
a significant improvement in lumbar spine and femoral neck
mean T-score value (from −1.9 ± 1.2 to −1.7 ± 1.3, 𝑃 = 0.015,
and from −1.8 ± 1.0 to −1.6 to 1.0, 𝑃 < 0.001, resp.) in the
76 patients (31 postmenopausal women, 36 postmenopausal
women, and 9 men) who underwent a reassessment of BMD
(Figure 2).
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−2
Figure 2: Bone mineral density (BMD) score improvement after 1-
year GFD in total population.
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Figure 3: Bone mineral density (BMD) score improvement after 1-
year GFD according to menopausal status.
In premenopausal women, GFD induced a significant
improvement in femoral T-score (𝑃 = 0.02) but not in
lumbar T-score (𝑃 = 0.064). The same results were observed
for postmenopausal women, with a significant improvement
in femoral T-score (𝑃 = 0.01) but not in lumbar T-score
(𝑃 = 0.22). Overall, pre/postmenopausal women’s data
are reported in Figure 3. Due to the small number of men
in the study, it is impossible to draw any conclusions on
improvement in men.
4. Discussion
In adults, bone remodeling has several functions: to repair
microdamage within the skeleton, to maintain skeletal
strength, and to supply calcium from the skeleton tomaintain
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Table 2: Bone mineral density (BMD) at lumbar spine scores according to sex and age.
𝑁 Healthy (%) Osteopenic (%) Osteoporotic (%) 𝑇-score lumbar spine
Male ≤ 30 y
(range 18–30) 9 77.8 11.1 11.1 −0.9 ± 1.0
Male 31–50 y 9 33.3 55.6 11.1 −1.5 ± 0.9
Male > 50 y
(range 51–70) 5 20 60 20 −1.0 ± 1.4
Female ≤ 30 y
(range 17–30) 37 45.9 43.3 10.8 −1.1 ± 1.2
Female 31–50 y 78 50 39.8 10.2 −1.0 ± 1.1
Female > 50 y
(range 52–75) 31 6.4 25.8 67.7 −2.6 ± 1.0
𝑁: number.
serum calcium levels. To better understand the fine details
of these events, several pathways of osteogenic induction are
under scrutiny [16]. The alterations of these functions, due
to several causes, can lead to osteopenia or osteoporosis.
While an inflammatory pattern is more plausible in the
pathogenesis of osteoporosis occurring in patients with IBD
[17], a combination of malabsorption and inflammation
contributes to low BMD in CD patients. Intestinal mucosal
lesion can lead to calcium malabsorption and decreased
levels of serum calcium [18–20] along with hypovitaminosis
D [20, 21]. Chronic release of proinflammatory cytokines
by immunologically competent cells of the gastrointestinal
mucosa might induce bone remodeling, stimulating bone
resorption by osteoclasts [22].
This single-center, prospective study investigates the
prevalence of low BMD and the effects of 1-year gluten
withdrawal in a cohort of adult patients with new diagnosis
of CD.
The prevalence of low BMD (osteoporosis and osteope-
nia) at the moment of CD diagnosis was 58%, but it is
not easy to compare our data with those available in the
literature [18, 23–25] due to the variability of characteristics
(age, sex, Marsh stage, and pre- and postmenopausal status)
of the individuals included in those studies. Nevertheless, it
is important to identify the patients who are most at risk of
fractures, to evaluate the different possibilities of surveillance
and treatment. In the present study, females/males ratio was
higher compared to other reports [26]. A large number of
males were excluded because of their refusal to repeat DXA
1 year after the diagnosis or repeated DXA out of date.
In fact, the proportion of males that repeated DXA 1 year
after CD diagnosis was only 12%. In our cohort, there was
no significant difference in lumbar/femoral T-score mean
values between males and females. BMD scores according
to Marsh III stage did not show any statistically significant
difference. Garc´ıa-Manzanares et al. [27] found that the stage
of duodenal mucosal injury (following Marsh classification)
was the most important factor in determining low BMD at
diagnosis but they considered differences between Marsh I,
Marsh II, and Marsh III grades unlike our study design.
A higher prevalence of low BMD was observed in men
older than 30 years and women of all ages, indicating that
these groups should be considered candidates for DXA scan
at the moment of CD diagnosis. Furthermore, our study
shows that 1 year of dietary treatment led to a bone mass
improvement as reported in other studies [23–25, 28, 29].
Finally, as the main consequence of osteoporosis is the
increased fracture risk, and the latter in these individuals
seems to be modest [12], performing DXA routinely in all
newly diagnosedCDpatients cannot be considered. It ismore
appropriate to select those patients who are at higher risk of
fractures for DXA. Thus, although some authors proposed
that a screening should be performed in all cases, either at the
time of diagnosis or after 1 year of GFD [12, 30, 31], we believe
that the modest increase in fracture risk does not justify the
costs of such screening [32].
Some critical issues should be considered. The retrospec-
tive design of the study represents a limitation: in fact, in real
life, control biopsies after 1 year of GFD are performed only
in NRCD, while control biopsies would be useful to check if
there is a correlation between a lack of improvement of BMD
after one year of GFD and a lack of complete normalization
of duodenal lesions despite symptoms disappearance and
negative CD related serology [33].
In the literature, prevalence of osteoporosis in celiac
disease is increased at the lumbar spine, but it is uncom-
mon at femoral neck; axial bone mass increases more than
appendicular mass during GFD therapy [34]. In our study
DXA scan of the lumbar spine resulted in osteoporosis in
21% of patients, while DXA scan of the femoral neck resulted
in osteoporosis in 13% of patients; a 1-year GFD led to a
significant improvement in lumbar spine and femoral neck
mean T-score value (𝑃 = 0.015 and 𝑃 < 0.001, resp.).
The improvement in BMD occurs mostly within the first
year; some patients diagnosed in adulthood run the risk of
maintaining a low BMD. Since BMD improves after 1 year
of GFD [35], it would be reasonable to repeat DXA at this
time and to start a supplementation therapy with calcium and
vitamin D only in patients without an improvement of BMD
after the GFD.
5. Conclusions
In conclusion, we propose to perform DXA at diagnosis of
CD in all women and inmen older than 30 years, considering
in each patient all the potential risk factors (age, prior
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osteoporotic fracture, family history of hip fracture, low body
mass index, use of drugs like corticosteroids, smoking, and
alcohol excess). Long-term studies are however needed to
evaluate the contribution of these factors to risk of fractures
in CD patients.
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